Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (September 2018)
32 slides from Streamex's investor presentation, Sep 18, 2018
Slide 1: Investor Presentation September 2018
F. Fi i Presentation r September 2018 Kenneth L: Londoner
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: Introduction to BioSig & Bioelectronic Medicine
Introduction to BioSig & Bioelectronic Medicine SYMBOL: BSGM
Slide 4: BioSig Technologies at a Glance
BioSig Technologies at a Glance ® . » Received FDA clearance for & first product, PURE EP™ © Founded in 2009; System, in Q3 2018 - targeting on strong path to $4.6B electrophysiology human clinical i isle and market, Bowing 10% annually revenues in 2019 - ° ° © Top 25 shareholders © Raised over $45
Slide 5: Our Vision
OUR VISION 1 Sikes Ree AoEEG Leader in Bioelectronic Me - A rapidly growing fiel healthcare Ss, that explores how targeted electrical signals can harness the body’ s natural mechanisms to diagnose and treat a range of diseases SYMBOL: BSGM oe
Slide 6: Bioelectronic Medicine
BIOELECTRONIC MEDICINE = Potential for Diagnosie z and Curing Many.Diseases
Slide 7: An Exciting, Fast-Growing Market
An Exciting, Fast-Growing Market Bioelectronic Medicine: Major Market Segments, 2017 Global Market Size, 2017: $20 BILLION Global Growth in EP Devices, 2016-24: 10.6% " E 13 Boe eo SK g é £ = e 46 eon ko N Ss Cardiac Rhythm Electrophysiology Spinal Cord Deep Brain Management ‘Stimulation ‘Stimulatio
Slide 8: Big Players Starting to Take Note
Big Players Starting to Take Note Tech giants exploring healthcare space verily amazon —— BioSig: Medical device giants making investments fohmuenafohnen Medtronic Bost Screntific Advancing science for life™ PHILIPS C) Abbott Successful IlPOs, some with big-name funders We electroCore” “74 4@ Neuron
Slide 9: A Game-Changing Solution
A Game-Changing Solution SYMBOL: BSGM
Slide 10: Our First FDA-Approved Product: PURE EP System
Our First FDA-Approved Product: PURE EP™ System BioSig SYMBOL: :BSGM
Slide 11: PURE EP System Comprises Two Proprietary Technologies
PURE EP™ System Comprises Two Proprietary Technologies Hardware Software PURE EP™ System Amplification Digital signal processing (DSP) Raw cardiac signal is displayed Analog-to-digital conversion with much sharper clarity » High fidelity unipolar recordings and less “noise” » PURE EP™ minimizes exce
Slide 12: Electrophysiology: Purest Application of Bioelectronic Medicine
Electrophysiology: Purest Application of Bioelectronic Medicine Normal Heartbeat Atrial Fibrillation Left Atrium Right Atrium SANode aL a ATRIAL FIBRILLATION — very prevalent » Rapid and irregular beating of the atria » Electrical impulses from the SA node in the right atrium are disturbed by rapid
Slide 13: Arrhythmia: A Challenging, Costly Disease
Arrhythmia: A Challenging, Costly Disease Atrial Fibrillation Ventricular Tachycardia Affects 33.5M ana hetweeh people... a Much rarer, but responsible 2.7M and 6.1M for most sudden cardiac in the U.S. deaths in the U.S., ~300,000 per year Contributes to Increases the risk 750,000 of stroke 4-5x Ind
Slide 14: Signal Clarity Paramount to Ablation Success
Signal Clarity Paramount to Ablation Success se www.fda.gov, BioSig SYMBOL: BSGM 14
Slide 15: Pure EP Value Proposition
Pure EP™ Value Proposition Potential benefits of PUREEP™ * Improves signal clarity, reduces “noise” CURRENT * May allowsurgeons to work more quickly and more accurately fold * May reduce likelihood/need for repeat procedure * Therefore, a better option for patients, i ™ bs ond fe “ of PURE EP physic
Slide 16: PURE EP Complements Existing EP Recording Devices
PURE EP™ Complements Existing EP Recording Devices Works in parallel with Does not compete head- A new product category: other lab systems, on with big device makers EP information system providing a clearer signal for clinicians Boston, Scientific ‘Advancing science for life™ Cc) Abbott | @ GE Heal
Slide 17: Clear Path to Commercialization & Growth
Clear Path to Commercialization & Growth SYMBOL: BSGM
Slide 18: PURE EP Developed Through Collaboration with Leading Centers of Excellence
PURE EP™ Developed Through Collaboration with Leading Centers of Excellence 2011 2013 2014 2014 2015 Concept developed Proof of concept test Prototype test Initial pre-clinical First pre-clinical with Texas Cardiac completed at UCLA with UCLA planning — trials at Mayo Arrhythmia Institute Health Hea
Slide 19: Key Scientific Publications
Key Scientific Publications The Joumal of Innovations in Cardiac Rhythm Management (April 2017) “Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Laboratory Experience” » PURE EP™ signal acquisition allows display of both raw and filtered signals, enabling better visual
Slide 20: Path to Commercialization
Path to Commercialization 2018 2019 2020 pe FDA 510(k) clearance Create clinical trial registry First installations at TCAI Develop clinical trial protocol and Mayo Clinic Introduce PURE EP™ system to First-in-man data medical centers nationwide Nasdaq listing Collect first revenues Receive CE mark
Slide 21: hardware configurations of the [PURE EP™] s m for mapping and recordit iz
hardware configurations of the [PURE EP™] s m for mapping and recordit iz es signals in fields like neurology and ophthalmology, in orderto better be able to _ characterize regional electrical activity.” — Authors of “Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Lab
Slide 22: Unique Collaboration with Mayo Clinic
Unique Collaboration i Ctinic with Mayo Clinic 10-year strategic agreement Explore new disease areas and - Defines collaborative work plan applications, leading to: - Spells out IP protection for both parties ~ Joint IP filings _ ~ Licensing opportunities Develop advanced clinical features Sepp and
Slide 23: Proven Credentials for Success
Proven Credentials for Success SYMBOL: BSGM
Slide 24: Distinctive Leadership Skill Set
Distinctive Leadership Skill Set ? Technological Capital markets Success in EP/medtech Intellectual savvy expertise building strong industry property businesses knowledge expertise “: BioSig’ ig SYMBOL: BSGM 24
Slide 25: Seasoned Management Team
Seasoned Management Team Natasha Drapeau seieiis Lainey Executive Vice President Founder, Chairman, CEO, Director Endicott Founder, Augeous Consulting, Geneva; International Management Partners, LLC; J & W Seligman &Co. Business Development Manager, IG Group Plc, London Steve Chaussy CEs Lora Mikola
Slide 26: Expert Advisory Board
Expert Advisory Board Sim Ramachandra Kent Bennett Farar yf Malya, MD Williams 30+ years of AO years in medicine q 30+ years in capital public/private-sector (nephrology) and markets, strategic leadership, including healthcare start-ups investments and chair of U.S. Advisory business development Com
Slide 27: World-Class Board of Directors
World-Class Board of Directors Kenneth L. Londoner, MBA peace BioSig BA] 2017 tanata sagagvese —— UMLEAND rons Seth H. Z. Fischer Gohmsen aGohnson Vivus: PatrickJ.Gallagher, MBA,CFA — “cinGuyzare’ Aiftene |e | Jeffrey F. O’Donnell, Sr. Trice — | empréta cBostany. Ea Andrew Filler Aw Gye] —wNanosys.
Slide 28: Robust IP Strategy, Supported by Experts
Robust IP Strategy, Supported by Experts ) Sterne Kessler STERNE KESSLER GOLDSTEIN & FOX SYMBOL: BSGM 28
Slide 29: The Buzz Is Building
The Buzz Is Building Los ANGELES BUSINESS JOURNAL D Ic BioSig Tech Gets Federal Green Light to Sell, Des ‘Medical Dev ‘oS Technologies Announce FDA STON Clernce for Pare © System BioSig he to Watel SYMBOL: BSGM 29
Slide 30: Key Financials
Key Financials OTCQB: BSGMD OTCQB:BSGM WWW.BIOSIGTECH.COM Key Company Data (9/17/18) Recent price: $5.44 52-week range: $3.12 - $7.88 Primary shares i/o: 16.134 million Public float: 11.780 million Market cap: $87.75 million Average volume (90 day): 64,836 shares SYMBOL: BSGM 30
Slide 31: BioSig Investment Highlights
BioSig Investment Highlights + BioSig’ Targeting $4.6B+ EP market. growing 10% p.a. FDA product clearance achieved; CE mark expected soon Uplisting to Nasdaq national exchange World-class management, board, advisors |P expertise from Sherpa Technology Group, Sterne Kessler 10-year strategic collabor
Slide 32: Contact Us
Contact Us Ken Londoner Natasha Drapeau Founder, Chairman & CEO Executive Vice President +1 (203) 644-5200 +1 (512) 329-2643 klondoner@biosigtech.com ndrapeau@biosigtech.com ‘This document is being provided on a confidential basis by BioSig Technologies, Inc. solely forthe information of those perso
BioSig Technologies — Investor Presentation (September 2018) on 6ix